

Global Fund TB Investments: Accelerating Progress Towards Impact

Eliud Wandwalo

Senior TB Coordinator, Global Fund

47th Union Conference, Liverpool, 27th Oct, 2016


 The Global Fund



Content Overview


- TB investments
- Current implementation and lessons
- Future: Next implementation period

Global Fund Disbursements by Disease Component




Component	Disbursements
HIV	\$ 16,558,711,312
Malaria	\$ 8,770,344,260
TB	\$ 4,923,850,080
TB-HIV	\$ 480,972,856
Other	\$ 591,129,247
Total	\$ 31,325,007,755

NUMBER OF LIVES SAVED THROUGH GLOBAL FUND-SUPPORTED PROGRAMS




People tested and treated for TB

NUMBER OF PEOPLE (SMEAR-POSITIVE) TREATED FOR TUBERCULOSIS (2002-2015)




Where are we investing? (1)



Top TB countries



- India
- Nigeria
- Philippines
- Myanmar
- Indonesia
- Bangladesh
- Ethiopia
- Kenya
- Pakistan
- Congo (Democratic Republic)
- All Others

The Global Fund is a major source of international funding for TB activities, including those for MDR-TB




Proportion of Global Fund cumulative expenditure for MDR-TB among all TB expenditures - has reached 30%

NFM: Where are we investing?-Modules (2)




NFM: Where are we investing?-intervention (3)


DS-TB




MDR-TB



Childhood TB: low investment (0.8%)




TB/MDR-TB Interventions rely heavily on strong functional health systems




Current implementation and lessons

Speed-up implementation and absorption of the current grant





Trends in TB Disbursements 2002-2016 and Projections 2016/17 (in \$1000s) (including TB/HIV)

Implementation Through Partnership: Where are bottlenecks?



1B. Level of ambition: Good grant performance are we making progress?





Each boxplot represents one priority country and shows distribution of % grant target met in each reporting period over 2012-2015

But global case detection is stagnating


modest targets?

Joint TB/HIV CN lead to joint implementation?




Source: GAC 2 budgets
 € values from Burkina Faso and Togo converted using grant specific exchange rate

Little progress in some TB/HIV indicators




HIV community lagging behind: Budgets for GeneXpert where does it come from?




Source: GAC 2 budgets
€ values from Burkina Faso and Togo converted using grant specific exchange rate

Preparation for next cycle

Global Fund Strategy 2017-2022 “Investing to End Epidemics”



- 
- Differentiated access to funding-support and process for pre-application stage?
 - No major changes on TB specific tools and materials (eg modules etc)
 - Major focus on finding missing cases both DS and MDR-TB (ie.Catalytic funding)
 - Emphasis on program quality and efficiency
 - Finalizing TB strategic investment information (ie. role of X-ray etc)

Key messages

- Scale up implementation and absorption of funds in 2016 and 2017
- While preparing for the next cycle 2017-2019 use lessons from the current implementation period
- Focus on implementation and maximizing impact;
 - Differentiation-in accessing funding and implementation
 - Improving program quality and efficiency

Thanks